Global Anti-tuberculosis Therapeutics Market Size (2024 - 2029)

The anti-tuberculosis therapeutics market is anticipated to experience growth driven by several factors, including the increasing prevalence of tuberculosis and the rising incidence of multi-drug resistant and extensively drug-resistant tuberculosis, particularly in developing countries. Government initiatives aimed at raising awareness about tuberculosis are also contributing to market expansion. However, the market's growth trajectory has been negatively affected by the COVID-19 pandemic, which disrupted healthcare services and resource allocation. Despite these challenges, the market's potential is supported by ongoing efforts to address tuberculosis through enhanced awareness and treatment initiatives.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Infectious Disease Drugs Research Anti-tuberculosis Therapeutics Industry Market Size

Market Size of Global Anti-tuberculosis Therapeutics Industry

Anti-Tuberculosis Drugs Market Summary
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.20 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Anti-Tuberculosis Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Anti-tuberculosis Therapeutics Market Analysis

The Anti-tuberculosis (TB) Therapeutics Market is expected to witness a CAGR of 6.2% during the forecast period (2022 - 2027).

The COVID-19 pandemic had a significant impact on the healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of diagnosis and treatment services to manage and reserve resources, and many hospitals are experiencing a shortage of professionals to assist with these diagnostic and treatment procedures. The COVID-19 restrictions imposed by the government have impacted the market growth. For instance, according to the data published by the World Health Organization, in March 2021, titled 'Impact of the COVID-19 pandemic on TB detection and mortality in 2020', it has been observed that an estimated 1.4 million fewer persons underwent TB treatment in 2020 than in 2019, a 21% decrease from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease, in June 2021, titled 'The impact of COVID-19 on TB: a review of the data, it has been observed that the provision of tuberculosis services has been hampered with high TB burden due to inadequate capacity and equipment, restrictions on migration (affecting health care staff, supplies, and stock), and resource reallocation. Also, tuberculosis patients have struggled to get TB services, either due to fear of SARS-CoV-2 infection, fear of stigma, mobility restrictions, shortened health facility operating hours, or reduced financial resources to pay for care or transportation. As a result, TB diagnosis, treatment, and prevention have been impacted globally. Thus, COVID-19 has significantly impacted the market growth during the pandemic.

Certain factors that are propelling the market growth are the rising prevalence of tuberculosis, a growing initiative from government organizations for tuberculosis awareness, and the rising incidence of multi-drug resistant (MDR) and extensively drug-resistant tuberculosis (XDR) cases in developing countries.

The COVID-19 pandemic had a significant impact on the healthcare systems, with significant consequences not only for COVID-19-infected patients but also for others, resulting in the cancellation of diagnosis and treatment services to manage and reserve resources, and many hospitals are experiencing a shortage of professionals to assist with these diagnostic and treatment procedures. The COVID-19 restrictions imposed by the government have impacted the market growth. For instance, according to the data published by the World Health Organization, in March 2021, titled 'Impact of the COVID-19 pandemic on TB detection and mortality in 2020', it has been observed that an estimated 1.4 million fewer persons underwent TB treatment in 2020 than in 2019, a 21% decrease from 2019. Additionally, as per an article published by the International Journal of Tuberculosis and Lung Disease, in June 2021, titled 'The impact of COVID-19 on TB: a review of the d, it has been observed that the provision of tuberculosis services has been hampered with high TB burden due to inadequate capacity and equipment, restrictions on migration (affecting health care staff, supplies, and stock), and resource reallocation. Also, tuberculosis patients have struggled to get TB services, either due to fear of SARS-CoV-2 infection, fear of stigma, mobility restrictions, shortened health facility operating hours, or reduced financial resources to pay for care or transportation. As a result, TB diagnosis, treatment, and prevention have been impacted globally. Thus, COVID-19 has negatively impacted the market growth during the pandemic.

Additionally, the rising incidence of multi-drug resistant tuberculosis (MDR-TB) and XDR in developing countries is also expected to boost market growth over the forecast period. For instance, according to an article published by the Journal of Family Medicine and Primary Care, in January 2022, titled 'Status of drug-resistant tuberculosis among patients attending a tuberculosis unit of West Bengal', it has been observed that the prevalence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB) is highest in India and ranks first in the global ranking of detecting new cases each year. In addition, as per the same source, an estimated overall incidence of tuberculosis in India was 193 per lakh people, in 2020.

Furthermore, the growing government initiatives in creating awareness among the population regarding tuberculosis (TB) are also expected to propel market growth over the forecast period. For instance, in March 2021, Dr. Harsh Vardhan, Union Minister for Health and Family Welfare launched the 'Tribal TB Initiative' along with Shri Arjun Munda, Union Minister for Tribal Affairs in the presence of Shri Ashwini Kumar Choubey, Minister of State for Health and Family Welfare in India. Also, in July 2019, the State Council of China released the Healthy China Initiative 2019-2030, which included 15 special campaigns, including the Tuberculosis Control Action to guide the way for China's TB prevention and control. Hnece, these factors are expected to boost the market growth.

However, the adverse side effects of anti-tuberculosis drugs and the high cost of MDR and XDR TB drugs are likely to impede the market growth over the forecast period.

Anti-tuberculosis Therapeutics Industry Segmentation

As per the scope of the report, Tuberculosis (TB) is a disease affecting the population across the world. Although tuberculosis is a curable disease, it remains one of the most common causes of death among adults, particularly in emerging economies. The Anti-tuberculosis Therapeutics Market is segmented by Drug Class (Isoniazid, Rifampin, Ethambutol, Pyrazinamide, Fluoroquinolones, Bedaquiline, Aminoglycosides, Thioamides, Cyclic Peptides, and Other Drug Classes), End User (Hospitals and Clinics, Government Agencies, Non-Profit Organizations, and Other End Users), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Drug Class
Isoniazid
Rifampin
Ethambutol
Pyrazinamide
Fluoroquinolones
Bedaquiline
Amynoglycosides
Thioamides
Cyclic Peptides
Other Drug Classes
By End User
Hospitals and Clinics
Government Agencies
Non Profit Organizations
Other End Users
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Anti-tuberculosis Therapeutics Market Size Summary

The anti-tuberculosis therapeutics market is poised for growth, driven by the increasing prevalence of tuberculosis and the rising incidence of multi-drug resistant and extensively drug-resistant cases, particularly in developing countries. Government initiatives aimed at raising awareness and improving TB control measures are also contributing to market expansion. However, the market faced challenges during the COVID-19 pandemic, which disrupted TB diagnosis and treatment services due to resource reallocation and healthcare system strains. Despite these setbacks, the market is expected to recover and grow, supported by the ongoing development and adoption of effective therapeutics, such as isoniazid, which is gaining traction due to its efficacy in treating TB strains with specific mutations.

North America is anticipated to lead the market, bolstered by a well-established healthcare infrastructure and significant healthcare spending, which facilitates the development of novel TB drugs. The region's increasing TB cases underscore the demand for effective therapeutics, driving market growth. The market is characterized by a high level of consolidation, with a few major companies holding substantial shares. However, the focus on research and development is expected to attract more small to mid-sized companies, fostering competition and innovation. Collaborative efforts, such as those by Johnson & Johnson and TB Alliance, highlight the industry's commitment to addressing the global TB burden through strategic partnerships and licensing agreements.

Explore More

Global Anti-tuberculosis Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Tuberculosis

      2. 1.2.2 Growing Initiative from Government Organization for Tuberculosis Awareness

      3. 1.2.3 Rising Incidence of MDR and XDR Cases in Developing Countries

    3. 1.3 Market Restraints

      1. 1.3.1 Adverse Side Effects of Anti-tuberculosis Drugs

      2. 1.3.2 High Cost of MDR and XDR TB Drugs

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 2.1 By Drug Class

      1. 2.1.1 Isoniazid

      2. 2.1.2 Rifampin

      3. 2.1.3 Ethambutol

      4. 2.1.4 Pyrazinamide

      5. 2.1.5 Fluoroquinolones

      6. 2.1.6 Bedaquiline

      7. 2.1.7 Amynoglycosides

      8. 2.1.8 Thioamides

      9. 2.1.9 Cyclic Peptides

      10. 2.1.10 Other Drug Classes

    2. 2.2 By End User

      1. 2.2.1 Hospitals and Clinics

      2. 2.2.2 Government Agencies

      3. 2.2.3 Non Profit Organizations

      4. 2.2.4 Other End Users

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Global Anti-tuberculosis Therapeutics Market Size FAQs

The Global Anti-tuberculosis Therapeutics Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)

Macleods Pharmaceuticals Ltd, Otsuka Pharmaceutical Co. Ltd, Johnson and Johnson, Sequella, Inc. and Lupin Limited are the major companies operating in the Global Anti-tuberculosis Therapeutics Market.

Anti-tuberculosis Therapeutics Market Report Snapshots

Anti-tuberculosis Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)